Lymph node-positive prostate cancer: Current issues, emerging technology and impact on clinical outcome

Julia Adams, Liang Cheng

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Lymph node metastasis in patients with prostate cancer indicates a poorer prognosis compared with patients without lymph node metastasis; however, some patients with node-positive disease have long-term survival. Many studies have attempted to discern what characteristics of lymph node metastasis are prognostically significant. These characteristics include nodal tumor volume, number of positive lymph nodes, lymph node density, extranodal extension, lymphovascular invasion and tumor dedifferentiation. Favorable characteristics of regional lymph node involvement included a smaller tumor size and smaller tumor volume. However, the current staging system for prostate cancer does not provide different subclassifications for patients with node-positive prostate cancer. In recent years numerous advanced technologies for the detection of lymph node metastasis have been developed, including molecular imaging techniques and the CellSearch ® Circulating Tumor Cell System. With the increased detection of patients with prostate cancer, emergence of new technology to identify lymph node metastasis and the number of radical prostatectomies being performed on the rise, subclassifying patients with lymph node-positive disease is imperative. Subclassification would provide a better picture of patient prognosis and allow for a better understanding of targeted therapies to treat patients with lymph node metastasis.

Original languageEnglish (US)
Pages (from-to)1457-1469
Number of pages13
JournalExpert Review of Anticancer Therapy
Volume11
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

Prostatic Neoplasms
Lymph Nodes
Technology
Neoplasm Metastasis
Tumor Burden
Circulating Neoplastic Cells
Molecular Imaging
Prostatectomy
Neoplasms
Survival

Keywords

  • cancer volume
  • dedifferentiation
  • metastasis
  • pelvic lymphadenectomy
  • prognosis
  • prostate
  • sentinel node
  • staging and classification

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Lymph node-positive prostate cancer : Current issues, emerging technology and impact on clinical outcome. / Adams, Julia; Cheng, Liang.

In: Expert Review of Anticancer Therapy, Vol. 11, No. 9, 01.09.2011, p. 1457-1469.

Research output: Contribution to journalReview article

@article{f71723f3a70744b8a7c04c9ac35322ed,
title = "Lymph node-positive prostate cancer: Current issues, emerging technology and impact on clinical outcome",
abstract = "Lymph node metastasis in patients with prostate cancer indicates a poorer prognosis compared with patients without lymph node metastasis; however, some patients with node-positive disease have long-term survival. Many studies have attempted to discern what characteristics of lymph node metastasis are prognostically significant. These characteristics include nodal tumor volume, number of positive lymph nodes, lymph node density, extranodal extension, lymphovascular invasion and tumor dedifferentiation. Favorable characteristics of regional lymph node involvement included a smaller tumor size and smaller tumor volume. However, the current staging system for prostate cancer does not provide different subclassifications for patients with node-positive prostate cancer. In recent years numerous advanced technologies for the detection of lymph node metastasis have been developed, including molecular imaging techniques and the CellSearch {\circledR} Circulating Tumor Cell System. With the increased detection of patients with prostate cancer, emergence of new technology to identify lymph node metastasis and the number of radical prostatectomies being performed on the rise, subclassifying patients with lymph node-positive disease is imperative. Subclassification would provide a better picture of patient prognosis and allow for a better understanding of targeted therapies to treat patients with lymph node metastasis.",
keywords = "cancer volume, dedifferentiation, metastasis, pelvic lymphadenectomy, prognosis, prostate, sentinel node, staging and classification",
author = "Julia Adams and Liang Cheng",
year = "2011",
month = "9",
day = "1",
doi = "10.1586/era.11.104",
language = "English (US)",
volume = "11",
pages = "1457--1469",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Lymph node-positive prostate cancer

T2 - Current issues, emerging technology and impact on clinical outcome

AU - Adams, Julia

AU - Cheng, Liang

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Lymph node metastasis in patients with prostate cancer indicates a poorer prognosis compared with patients without lymph node metastasis; however, some patients with node-positive disease have long-term survival. Many studies have attempted to discern what characteristics of lymph node metastasis are prognostically significant. These characteristics include nodal tumor volume, number of positive lymph nodes, lymph node density, extranodal extension, lymphovascular invasion and tumor dedifferentiation. Favorable characteristics of regional lymph node involvement included a smaller tumor size and smaller tumor volume. However, the current staging system for prostate cancer does not provide different subclassifications for patients with node-positive prostate cancer. In recent years numerous advanced technologies for the detection of lymph node metastasis have been developed, including molecular imaging techniques and the CellSearch ® Circulating Tumor Cell System. With the increased detection of patients with prostate cancer, emergence of new technology to identify lymph node metastasis and the number of radical prostatectomies being performed on the rise, subclassifying patients with lymph node-positive disease is imperative. Subclassification would provide a better picture of patient prognosis and allow for a better understanding of targeted therapies to treat patients with lymph node metastasis.

AB - Lymph node metastasis in patients with prostate cancer indicates a poorer prognosis compared with patients without lymph node metastasis; however, some patients with node-positive disease have long-term survival. Many studies have attempted to discern what characteristics of lymph node metastasis are prognostically significant. These characteristics include nodal tumor volume, number of positive lymph nodes, lymph node density, extranodal extension, lymphovascular invasion and tumor dedifferentiation. Favorable characteristics of regional lymph node involvement included a smaller tumor size and smaller tumor volume. However, the current staging system for prostate cancer does not provide different subclassifications for patients with node-positive prostate cancer. In recent years numerous advanced technologies for the detection of lymph node metastasis have been developed, including molecular imaging techniques and the CellSearch ® Circulating Tumor Cell System. With the increased detection of patients with prostate cancer, emergence of new technology to identify lymph node metastasis and the number of radical prostatectomies being performed on the rise, subclassifying patients with lymph node-positive disease is imperative. Subclassification would provide a better picture of patient prognosis and allow for a better understanding of targeted therapies to treat patients with lymph node metastasis.

KW - cancer volume

KW - dedifferentiation

KW - metastasis

KW - pelvic lymphadenectomy

KW - prognosis

KW - prostate

KW - sentinel node

KW - staging and classification

UR - http://www.scopus.com/inward/record.url?scp=80053018951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053018951&partnerID=8YFLogxK

U2 - 10.1586/era.11.104

DO - 10.1586/era.11.104

M3 - Review article

C2 - 21929319

AN - SCOPUS:80053018951

VL - 11

SP - 1457

EP - 1469

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 9

ER -